Edition:
United Kingdom

Camurus AB (CAMX.ST)

CAMX.ST on Stockholm Stock Exchange

132.00SEK
18 Dec 2017
Change (% chg)

2.25kr (+1.73%)
Prev Close
129.75kr
Open
132.50kr
Day's High
133.25kr
Day's Low
129.50kr
Volume
47,022
Avg. Vol
29,306
52-wk High
145.75kr
52-wk Low
103.00kr

Chart for

About

Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a... (more)

Overall

Beta: --
Market Cap(Mil.): kr4,585.62
Shares Outstanding(Mil.): 37.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Camurus Q3 operating loss widens to SEK ‍67.1​ million

* Q3 NET REVENUE SEK ‍12.5​ MILLION VERSUS SEK 30.5 MILLION YEAR AGO

26 Oct 2017

BRIEF-Camurus and Braeburn announce submission of NDA for long-acting buprenorphine (CAM2038) for opioid use disorder

* CAMURUS AND BRAEBURN ANNOUNCE SUBMISSION OF NDA FOR LONG-ACTING BUPRENORPHINE (CAM2038) FOR OPIOID USE DISORDER

20 Jul 2017

BRIEF-Camurus Q2 operating loss widens to SEK ‍58.7​ mln

* Q2 REVENUE SEK ‍19.1​ MILLION VERSUS SEK 25.8 MILLION YEAR AGO

13 Jul 2017

BRIEF-Camurus and Braeburn Pharma announce phase 2 results for long-acting Buprenorphine in opioid dependent patients with chronic pain

* Camurus and Braeburn Pharmaceuticals announce topline phase 2 results for long-acting buprenorphine in opioid dependent patients with chronic pain

12 Jul 2017

BRIEF-Trial results suggest that Camurus' CAM2038 formulations would be effective in reducing illicit opioid use, relapse

* LONG-ACTING BUPRENORPHINE BLOCKS OPIOID EFFECTS AND SUPPRESSES WITHDRAWAL SYMPTOMS IN ADULTS WITH OPIOID USE DISORDER

22 Jun 2017

Earnings vs. Estimates